Emerging drugs for the treatment of hypercholesterolemia.

Emerging drugs for the treatment of hypercholesterolemia. Expert Opin Emerg Drugs. 2019 Mar 06;: Authors: Bove M, Cicero AFG, Borghi C Abstract Introduction Despite the consolidated role of statins and ezetimibe to treat hypercholesterolemia, often the desirable Low-Density-Lipoprotein-cholesterol (LDL-C) values are not achieved, with a consequent increase of the residual cardiovascular (CV) risk. Areas covered In this review, we summarize the main pharmacological characteristics of new lipid-lowering drugs, such as Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) Inhibitors, Cholesteryl-Ester-Transfer Protein inhibitors, Microsomal Triglyceride Transfer Protein inhibitors, ATP citrate lyase inhibitors, Antisense Oligonucleotides, small interfering RNA and Peroxisome Proliferator-Activated Receptors type α agonists. The available clinical evidence of efficacy and safety is critically discussed as well as the prospects of application, based on the different mechanisms and targets of action. Expert opinion Some of these emerging agents represent an excellent therapeutic strategy to treat patients with LDL largely out of target, resistant or intolerant to statins, trying to minimize the residual CV risk, modulating different classes of lipoproteins, not just LDL. The main challenge for the large use of emerging drugs is their cost. Thus, the correct identification of the adequate target population for treatment is a priority. This is particularly ...
Source: Expert Opinion on Emerging Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Related Links:

Publication date: Available online 11 July 2020Source: Diabetes &Metabolic Syndrome: Clinical Research &ReviewsAuthor(s): Ray Subir, Mukherjee Jagat J, Gangopadhyay Kalyan K
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
COVID, sacubitril/valsartan, left atrial appendage occlusion, and statins are the topics Dr John Mandrola discusses in this week ’ s podcast.theheart.org on Medscape
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology Commentary Source Type: news
AbstractRosuvastatin/ezetimibe combines two lipid-lowering agents: rosuvastatin, an HMG-CoA reductase inhibitor (i.e. statin) with particularly strong inhibitory effects on hepatic cholesterol synthesis, and ezetimibe, which inhibits the intestinal absorption of cholesterol. A fixed-dose combination (FDC) of rosuvastatin/ezetimibe is indicated as an adjunctive therapy to diet for the management of primary hypercholesterolemia in adults in numerous countries worldwide. In well-designed clinical trials evaluating the therapeutic efficacy of rosuvastatin/ezetimibe administered as either separate agents or as an FDC, rosuvasta...
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
AbstractIntroductionProprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are proven to have profound lowering of low-density lipoprotein cholesterol (LDL-C) in patients with clinical atherosclerotic cardiovascular disease or familial hypercholesterolemia.AimThe primary purpose of this study was to evaluate PCSK9i utilization in older adults, with a focus on efficacy outcomes within 6  months of initiation. Secondary outcomes included tolerability, out-of-pocket expenses (OPE), and barriers to initiation of therapy.MethodsWe conducted a retrospective chart review of patients ≥ 65 years prescribed P...
Source: High Blood Pressure and Cardiovascular Prevention - Category: Cardiology Source Type: research
Publication date: Available online 8 July 2020Source: Pharmacology &TherapeuticsAuthor(s): Ole Köhler-Forsberg, Christian Otte, Stefan M. Gold, Søren Dinesen Østergaard
Source: Pharmacology and Therapeutics - Category: Drugs & Pharmacology Source Type: research
With trial data for this age group in short supply, a US veterans cohort study saw a 25% drop in all-cause mortality for those newly starting on a statin at age 75 or older.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news
People 75 and older who were free of heart disease and prescribed a statin wound up with a 25% lower risk of death from any cause and a 20% lower risk of heart-related death, researchers reported July 7 in the Journal of the American Medical Association.
Source: WebMD Health - Category: Consumer Health News Source Type: news
Conclusion: The level of adherence to the recommendations of U.S. and Brazilian guidelines of dyslipidemia for statin use was low. Most patients used a moderate intensity statin, despite having a high cardiovascular risk. Simvastatin was the most prescribed statin. PMID: 32634034 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
AbstractPurpose of ReviewThe purpose of this review is to discuss the updated guideline recommendations on management of dyslipidemia for prevention and treatment of cardiovascular disease.Recent FindingsThe American College of Cardiology/American Heart Association (ACC/AHA) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) published revised cholesterol management guidelines in 2018 and 2019, respectively, to reflect new evidence in the field. Broadly speaking, both emphasize refining cardiovascular disease risk estimation and aggressively lowering low-density lipoprotein-cholesterol (LDL-C) wit...
Source: Current Cardiology Reports - Category: Cardiology Source Type: research
Publication date: October 2020Source: Pharmacological Research, Volume 160Author(s): Wenhui Xie, Hong Huang, Shiyu Xiao, Xinlei Yang, Zhuoli Zhang
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Drugs & Pharmacology | Heart | Statin Therapy | Vytorin | Zetia